EANS-Adhoc: Semperit AG Holding Impairment of approx. EUR 26 million in
Sempermed segment
--------------------------------------------------------------------------------
Disclosed inside information pursuant to article 17 Market Abuse Regulation
(MAR) transmitted by euro adhoc with the aim of a Europe-wide distribution.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information
27.07.2017
Vienna - On 10 April 2017, Semperit AG Holding announced in accordance with
Article 17 of the EU Market Abuse Regulation that the long-term earnings outlook
for the Sempermed segment (Medical Sector) had to undergo a critical review
compared with the previous assessment, which could result in a significant
impairment in the Sempermed segment.
Following an in-depth review, the Management Board of Semperit AG Holding has
come to the conclusion today that the sustainably achievable production volume
at the site in Kamunting, Malaysia, is lower than previously assumed. As a
result, an impairment of approximately EUR 26 million has to be recognised in
the interim consolidated financial statements as of 30 June 2017. Thus, based on
current knowledge, the goodwill of the segment will be completely impaired.
The exact amount of the impairment will be announced with the publication of the
half-year financial report 2017 on 17 August 2017.
Further inquiry note:
Martina Büchele
Group Communications Manager
Tel.: +43 676 8715 8621
martina.buechele@semperitgroup.com
Stefan Marin
Head of Investor Relations
Tel.: +43 676 8715 8210
stefan.marin@semperitgroup.comwww.semperitgroup.com
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: Semperit AG Holding
Modecenterstrasse 22
A-1030 Wien
phone: +43 1 79 777-210
FAX: +43 1 79 777-602
mail: stefan.marin@semperitgroup.com
WWW: www.semperitgroup.com
ISIN: AT0000785555
indexes: WBI, ATX GP
stockmarkets: Wien
language: English